Colin Powers
Overview
Explore the profile of Colin Powers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Powers C, Gunabushanam V, Centonze L, Humar A
Updates Surg
. 2025 Feb;
PMID: 39979551
The careful selection of donors is crucial to achieving a successful outcome in living donor liver transplantation. The evaluation process involves obtaining a comprehensive medical history and pertinent laboratory testing,...
2.
Cruz Jr R, Liu H, Khanna A, Colin P, Powers C, Gunabushanam V, et al.
Liver Transpl
. 2025 Jan;
PMID: 39792269
No abstract available.
3.
Powers C, Corrente B, Joyce J, Stein W, Polydor S, Gunabushanam V, et al.
Clin Transplant
. 2024 Dec;
39(1):e70065.
PMID: 39739932
Background: There has been significant concern about coronavirus disease 2019 (COVID-19) among transplant recipients, particularly those who are highly immunosuppressed. Several studies have analyzed the impact of COVID-19 on different...
4.
Elias C, Rahman A, Mial-Anthony J, Packiaraj G, Crane A, Alshamery S, et al.
Chin Clin Oncol
. 2024 Oct;
13(5):70.
PMID: 39390920
In recent years, significant progress has been made in the diagnosis, treatment, and palliation of cholangiocarcinoma (CC). CC accounts for 15% of all primary liver neoplasms and 3% of all...
5.
Kaltenmeier C, Liu H, Zhang X, Ganoza A, Crane A, Powers C, et al.
BJS Open
. 2024 Jun;
8(3).
PMID: 38837956
Background: For individuals with advanced liver disease, equipoise in outcomes between live donor liver transplant (LDLT) and deceased donor liver transplant (DDLT) is uncertain. Methods: A retrospective cohort study was...
6.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, et al.
Med
. 2024 Feb;
5(2):169-171.
PMID: 38340710
No abstract available.
7.
Mao L, Shaabani N, Zhang X, Jin C, Xu W, Argent C, et al.
Med
. 2024 Jan;
5(1):42-61.e23.
PMID: 38181791
Background: Oral antiviral drugs with improved antiviral potency and safety are needed to address current challenges in clinical practice for treatment of COVID-19, including the risks of rebound, drug-drug interactions,...
8.
Hu Q, Zhao Y, Shaabani N, Lyu X, Powers C, Sun H, et al.
Mol Ther Nucleic Acids
. 2022 Nov;
30:465-476.
PMID: 36345542
The emerging SARS-CoV-2 variants of concern (VOCs) exhibit enhanced transmission and immune escape, reducing the effectiveness of currently approved mRNA vaccines. To achieve wider coverage of VOCs, we first constructed...
9.
Cao X, Maruyama J, Zhou H, Fu Y, Kerwin L, Powers C, et al.
Sci Rep
. 2022 Sep;
12(1):15517.
PMID: 36109550
Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of...
10.
Duty J, Kraus T, Zhou H, Zhang Y, Shaabani N, Yildiz S, et al.
Med
. 2022 Aug;
3(10):705-721.e11.
PMID: 36044897
Background: The continual emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern, in particular the newly emerged Omicron (B.1.1.529) variant and its BA.X lineages, has rendered ineffective...